Related Experiment Video
Updated: Aug 6, 2025

An Experimental Paradigm for the Prediction of Post-Operative Pain PPOP
Published on: January 27, 2010
Effects of oxycodone pharmacogenetics on postoperative analgesia and related clinical outcomes in children: a pilot
Blessed W Aruldhas1,2,3, Sara K Quinney1,4,5, Senthil Packiasabapathy2
1Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Insights
Genetic variations in key genes influence how children process oxycodone, affecting their pain levels and recovery after surgery. This research identifies specific gene-outcome links for personalized pain management.
Area of Science:
- Pharmacogenomics
- Pediatric Surgery
- Pain Management
Background:
- Pharmacokinetic and pharmacodynamic variability of oxycodone in children is significant.
- Genetic polymorphisms are potential contributors to this variability.
- Understanding these genetic factors is crucial for optimizing pediatric pain management.
Purpose of the Study:
- To investigate the association between specific pharmacogenes and clinical outcomes in pediatric surgical patients.
- To explore the relationship between genetic variations and the effectiveness of oxycodone therapy.
- To identify genetic markers that predict pain scores and recovery in children.
Main Methods:
- A cohort of 89 children undergoing major surgery (pectus excavatum repair or spinal fusion) was studied.
- Genotyping was performed for relevant pharmacogenes, including OPRM1, PXR, COMT, and ABCB1.
- Clinical outcomes such as pain scores and length of hospital stay were recorded and analyzed.
Main Results:
- OPRM1 SNP rs6902403 was significantly associated with maximum pain scores and total opioid dosage.
- Other studied polymorphisms in OPRM1, PXR, COMT, and ABCB1 correlated with average opioid dosage, hospital stay duration, and maximum surgical pain.
- P-values < 0.05 indicated statistically significant associations.
Conclusions:
- This study reveals novel associations between specific pharmacogenes and oxycodone pharmacokinetics in children.
- Identified gene-outcome relationships offer potential for tailoring oxycodone treatment and improving postoperative outcomes.
- Findings support the role of pharmacogenetics in personalized pain management for pediatric surgical patients.
Abstract:
Background: Variability in the pharmacokinetics and pharmacodynamics of oxycodone in children undergoing surgery could be due to genetic polymorphisms. Materials & methods: The authors studied the association between clinical outcomes and pharmacogenes in children undergoing major surgery. A total of 89 children (35 undergoing pectus excavatum repair and 54 undergoing spinal fusion) were recruited. Results: OPRM1 SNP rs6902403 showed an association with maximum pain score and total morphine equivalent dose (p < 0.05). Other polymorphisms in OPRM1 SNP, PXR, COMT and ABCB1 were also shown to be associated with average morphine equivalent dose, length of hospital stay and maximum surgical pain (p < 0.05). Conclusion: This study demonstrates novel associations between the above pharmacogenes and oxycodone's pharmacokinetics as well as postoperative outcomes in children. Clinical trial registration: NCT03495388 (ClinicalTrials.gov).
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Parenteral Anesthetics: Overview
Local Anesthetics: Pharmacokinetics
Factors Affecting Drug Response: Overview

